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INTRODUCTION 
 
 As observed in many countries in the world, cardiovascular disease 
(CVD) remains the main cause of mortality and morbidity in Brazil. According 
to Brazilian Ministry of Health, from all recorded deaths and hospitalisations, 
29.6% and 12.1%, respectively, were related to CVD in 20131. Besides the 
impact on mortality and morbidity, its budget commitment is highly substantial. 
The Brazilian Public Health System spends no less than 8% of its budget to 
manage major cases of CVD 2.   
 Newer interventions for CVD are being developed and a platform to 
assess them in terms of efficiency does not exist within the Brazilian setting. 
Estimating efficiency of alternative interventions has also become relevant 3 
as its findings help taking decisions under uncertainty conditions. The aim is 
to determine which strategy is associated with the most benefit to each 
monetary unit invested. As a result, this ensures that scarce monetary 
resources are invested in a more rational manner 3.  
 CVD is a complex disease where a number of personal risk factors 
play a role to define the chance of experiencing CVD events and hence 
resource use. Thereafter, decision analyses using mean values from a 
population to populate pharmacoeconomic models are capable to predict 
costs and consequences for a narrow range of subjects, leading to limited use 
in decision-making 4,5. An individual-based approach seems to be the most 
appropriate methodology for predicting costs and consequences of 
interventions aiming to prevent primary CVD events 6. However, such studies 
demand an extensive dataset of patient-level data, what may not be available 
in several countries and for populations of interest.  
 One alternative is to adapt existing and well validated models for the 
desired population and perspective 7,8. From potential sources to be used 9–11 
the Scottish CVD Policy Model 12 was chosen for presenting a number of 
important aspects, as capability to predict risks for the most important CVD 
events annually; taking into account secondary events to predict morbidity 
and mortality; estimating risks through a competing risk framework and, finally 
incorporating the most relevant risk factors for CVD in the Brazilian population 
20,36.    
 We sought to adapt the Scottish CVD Policy Model 12 to predict life 
expectancy, incidence of coronary heart disease (CHD), cerebrovascular 
disease (CBVD), fatal CVD and fatal non-CVD events in the Brazilian 
population. 
  
 
METHODOLOGY 
  
 This model adaptation followed the best practices currently available in 
literature 7,13 and was performed separately for men and women. The diagram 
below describes the strategy created to adapt the Scottish Cardiovascular 
Disease Policy Model 12 to the Brazilian setting.  
Original Scottish CVD Policy Model 
 The Scottish CVD Policy Model was developed to assess interventions 
capable to prevent primary CVD events in Scotland 12. It consists of a state 
transition model based on patient-level data added to a time-to-event 
individual history approach, being described as a hybrid model. It is 
composed by four primary events CHD (ICD9 410-414; ICD10 I20-I25), CBVD 
(ICD9 430-438; ICD10 G45, I60-I69), fatal CVD (ICD9 390-459, ICD10 I00-
I99) and fatal non-CVD. A final transition to ‘death due to all cause’ following 
primary non-fatal event is also represented. An illustration of the state-
transition model is available in Appendix.  
 From the Scottish Heart Health Extended Cohort (SHHEC) 14,15 data, a 
survival analysis (Gompertz regression) was used to model the cause specific 
hazards of the first events. In addition, life expectancy after CHD and CBVD 
was also estimated by means of Gompertz regression. The choice for the 
risks factors was based on ASSIGN score, currently the risk calculator 
recommended by The Scottish Intercollegiate Guidelines Network to be used 
in Scotland 12. For predicting risks of the aforementioned primary CVD events, 
were considered: age (years), systolic blood pressure (SBP), total cholesterol 
(TC), HDL cholesterol (HDL), cigarettes per day (CPD), diagnosis of diabetes, 
family history of heart disease (FHHD) and SIMD score, a measure of 
socioeconomic deprivation. For secondary events, the non-modifiable risk 
factors age at first event, FHHD and SIMD score, were taken into account. 
Additional information is available elsewhere 12. 
 SIMD score 2004 is a specific tool for Scotland composed by six 
domains 21, current income, employment deprivation, health deprivation, 
education skills and training deprivation and geographic access and 
telecommunications deprivation. Its purpose is to serve as a tool for 
measuring level of deprivation in different areas across the country. In order to 
make possible running the model, it was estimated an artificial correspondent 
SIMD score for Brazil. Limitations and opportunities about this subject were 
discussed. 
Defining target data  
 Target data is an empirical data the model needs to reproduce 13. For 
life-expectancy, Brazilian Life-Table 17was chosen as it is a real-world data 
representative of entire country. Target data for incidence of the events CHD, 
CBVD, fatal CVD and fatal non-CVD corresponded to a Brazilian Cohort study 
entitled Brazilian Population-based Cohort Study 20. It consisted of a 
population-based research, in which 1,091 participants from the city of Porto 
Alegre were enrolled. Limitations of selected dataset were further discussed. 
Assessing need of calibration 
 For the sake of clarity, risk factors data for a given subject are now 
referred as profile.  
 
Life expectancy 
 Since it was not expected to find profiles for Brazilian adults without 
history of CVD events, it was retrieved from official reports 16–19 average data 
of Brazilians aging 35 years or more. The assumption of both populations 
having similar profiles is reasonable, as most part of individuals have not 
experienced CVD events. When data was not present in official reports, a 
systematic review was carried out to identify studies capable to estimate 
them. From these data, it was generated a simulated cohort of 1,000 profiles 
to be used in the calibration process by considering variance of identified 
data. Normal distribution was applied to age, SBP, TC and HDL. Beta 
distribution was set to prevalence of diabetes and FHHD whereas Gamma 
distribution for CPD.   
 Prevalence of diabetes in Brazil was retrieved for different ages and 
sex, from Telephone-based Surveillance of Risk and Protective Factors for 
Chronic Diseases report (2014) 16. FHHD was estimated regardless sex or 
age considering the number of families 1 and diagnosis of CVD in 2013 18. 
The average SBP was calculated taking into account the prevalence of 
hypertension 22, the estimated proportion of controlled hypertensive patients 23 
and the average SBP for normotensives, controlled and uncontrolled 
hypertensive patients 24,25. Estimates for CPD considered the percentage of 
individuals who smoke more and less than 20 cigarettes per day 16. Mean and 
variances for both groups were estimated taking into account sex and age 26. 
A systematic search in databases Medline, EMBASE and SciELO (Scientific 
Electronic Library Online) was carried out to identify studies reporting results 
for lipid profile of Brazilian population. It was identified nine studies which 
complied with inclusion criteria comprising 4,781 individuals from seven 
different national states 27–35. Data from TC and HDL of patients who have 
never experienced CVD events were collected and an overall estimate 
according to sex and age was calculated. A summary of those profiles is 
available in Appendix.  For each random profile was assigned a 
corresponding life expectancy 17 according to baseline age.      
 
Incidence of CHD, CBVD, fatal CVD and non-CVD 
 To assess the necessity of calibrating incidence for the primary CVD 
events, mean values of risk factors were retrieved from the Brazilian Cohort 
study 20. Average prevalence of diabetes, FHHD, SBP, TC, HDL and CPD, 
separated by genre, were obtained for six ranges of age (30-39; 40-49; 50-59; 
60-69; 70-79; 80-more) during a follow-up of seven years. It was randomly 
generated 1,000 profiles by considering variance of each risk factor. Normal 
distribution was applied to age, SBP, TC and HDL. Beta distribution was set 
to prevalence of diabetes and FHHD whereas Gamma distribution to CPD.  
 For each range of age, separated by sex, yearly incidences of primary 
CVD events were obtained. Cumulative incidence was calculated by means of 
the equation:  𝐶𝐶𝐶𝐶𝑘𝑘(𝑡𝑡) = ∑𝑝𝑝𝑘𝑘𝑡𝑡𝑗𝑗. 
The cumulative incidence at time 𝑡𝑡,  𝐶𝐶𝐶𝐶𝑘𝑘(𝑡𝑡), is the sum of the unconditional 
probabilities, 𝑝𝑝, of experiencing event 𝑘𝑘 at time 𝑡𝑡𝑗𝑗. The four primary events are 
competing among each other. Hence, care was taken to avoid 
overestimations.  
 
Acceptance criteria, algorithm search and stopping rule 
 Assessing the necessity of calibration consisted of comparing predicted 
life expectancy and risk of each of the four assessed primary CVD events for 
a given profile, with observed data (target data). When acceptance criteria 
were not complied, a calibration was undertaken. For life expectancy, 
acceptance criteria consisted of observing absolute differences equal or 
lesser than one year between predicted and observed data. For the risk of 
each CVD event, acceptance criteria were defined as an absolute difference 
equal or lesser than 1% between predicted and observed data.  
  A pragmatic approach was performed when calibration was required, 
by adjusting linear prediction of the first four events. For the Gompertz 
regression, cause specific hazard for event 𝑘𝑘  at time 𝑡𝑡𝑗𝑗 is obtained by the 
equation: 
ℎ𝑘𝑘�𝑡𝑡𝑗𝑗� = 𝑒𝑒𝑒𝑒𝑝𝑝(𝑒𝑒𝑥𝑥) 𝑒𝑒𝑒𝑒𝑝𝑝 (𝛾𝛾𝑡𝑡). 
Linear predictor is represented by 𝑒𝑒𝑥𝑥 and 𝛾𝛾 corresponds to the ancillary 
parameter. Therefore, calibration was statistically expressed as: 
ℎ𝑘𝑘�𝑡𝑡𝑗𝑗� = 𝑒𝑒𝑒𝑒𝑝𝑝[(𝑒𝑒𝑥𝑥)(𝐶𝐶𝐶𝐶)] 𝑒𝑒𝑒𝑒𝑝𝑝 (𝛾𝛾𝑡𝑡). 
Where CF is the calibration factor. It was assumed CF of 1.00 in the original 
model. An algorithm running through different values of CF was undertaken 
for life expectancy and the cumulative incidences of the first four events. 
Differences between predictions and observed data were explored by root 
mean square error (RMSE). Therefore, calibration had the goal of decreasing 
RMSE up to a point when acceptance criteria are met. Stopping rule 
consisted of running the model with all identified CFs and meet acceptance 
criteria for all target data simultaneously.  
Population eligible to be assessed in the adapted model 
 From all random profiles tested during adaptation, it was summarized 
characteristics of those that met acceptance criteria after calibration. 
Potentially, the adapted model is capable to predict correctly life expectancy 
and cumulative incidence of CHD, CBVD, fatal CVD and fatal non-CVD 
events for individuals with such a profile.  
RESULTS 
 
 As previously described, real-world data was linked to each profile 
randomly generated. Profiles used for life expectancy assessment were 
estimated by means of national reports. For cumulative incidence of primary 
CVD events, profiles were estimated by taking into account mean 
characteristics of subjects enrolled in the Brazilian Cohort study 20. Each 
created profile aimed to be representative of existing profiles within Brazilian 
population, given sex and age. Full description of these profiles is provided in 
Appendix.  
 Data from both official reports Brazilian National Household Sample 
Survey 2012 19 and Health Informatics Department of the Brazilian Ministry of 
Health 1 were used for obtaining a SIMD score of 65.13 following the 
methodology reported elsewhere 21. Variations in SIMD score alter 
significantly the risks predicted from adapted model. Nevertheless, since the 
calibration process was performed considering the value of 65.13, the 
importance of this parameter was nullified. 
Life expectancy checking 
 Original model underestimated life expectancy when compared to 
findings reported in Brazilian life table in more than one year for men and 
women (RMSE=2.85 and 1.91, respectively). It was run the calibration 
algorithm and the multiplicative factor that complied with the stopping rule was 
the linear regression 𝑪𝑪𝑪𝑪 = 𝟎𝟎.𝟎𝟎𝟎𝟎𝟎𝟎𝟎𝟎 ×  𝒂𝒂𝒂𝒂𝒂𝒂 + 𝟎𝟎.𝟖𝟖𝟖𝟖𝟖𝟖  for men and 𝑪𝑪𝑪𝑪 =
𝟎𝟎.𝟎𝟎𝟎𝟎𝟎𝟎𝟎𝟎 ×  𝒂𝒂𝒂𝒂𝒂𝒂 + 𝟎𝟎.𝟗𝟗𝟗𝟗𝟗𝟗 for women. Thus, linear predictors for fatal-CVD and 
fatal non-CVD primary events were calibrated by those functions. Comparison 
of predicted and observed life expectancy after calibration resulted in 
RMSE=0.61 for men and 0.21 for women (Figure 2).  
 From all random profiles used to assess life expectancy predictions, 
96% and 95% met the acceptance criteria after calibration for men and 
women, respectively. Disagreements were observed for profiles with age 
greater than 70 years old.    
 
Checking cumulative incidence for primary events (CHD, CBVD, fatal 
CVD and non-CVD) 
 Profiles obtained from the cohort study 20 for different sex and ages 
and which were used to assess predictions for primary events, are described 
in the appendix. For male, comparison between predictive and observed 
cumulative incidences of CBVD, fatal CVD and fatal non-CVD complied with 
the acceptance criteria. On the other hand, for predicted CHD event was 
identified an important difference between prediction and observed data, 
varying from 0.50-2.10% throughout the seven years of follow-up 
(RMSE=0.031). Therefore, calibration was conducted by means of the already 
described algorithm, which pointed the multiplicative factor 1.05 as capable to 
adjust the differences observed, resulting in RMSE=0.008. As an implication 
of it, the linear predictor for non-fatal CHD passed to be multiplied by 1.05 
(figure 3).  
 For female model, predicted and observed cumulative incidences of 
fatal CVD and fatal non-CVD met the acceptance criteria. However, such 
fitting was not observed for CHD and CBVD events, where an absolute 
difference of 0.2-1.6% (RMSE=0.044) and 0.4-2.0% (RMSE=0.041), 
respectively, was observed across the seven years of follow-up. Calibration 
algorithm was run and pointed the multiplicative factor 0.98 (RMSE=0.016) 
and 0.93 (RMSE=0.017), respectively, as the most appropriates for each 
event (figure 3).       
 In men and women, respectively, 81% and 79% of profiles met 
acceptance criteria of all target data after calibration. Profiles involving older 
people (more than 70 years-old), having all risk factors under control, 
presenting extreme high values of SBP (SBP>190 mmHg), TC (TC>300 
mg/dL), HDL (HDL>80 mg/dL) or CPD (more than 60 CPD) were responsible 
for disagreements between observed data and predictions.    
 
DISCUSSION 
 This is the first study to introduce an individual-based decision analytic 
model for Brazilian individuals with the goal of assessing interventions to 
prevent primary cardiovascular events. That model has the potential to adjust 
for background morbidity impacts and subsequent consequences of 
experiencing first and following CVD events. Furthermore, prevention of 
primary CVD events is likely to extend life expectancy, what in turns lead to 
individuals accumulating comorbidities, impacting directly in costs, as 
hospitalisation episodes, and quality of life. All these conditions were taken 
into account for estimating costs and quality-adjusted life years.          
 Four main reasons justify choosing risk equations from Scottish CVD 
Policy Model over other existing options to build this first version of the 
Brazilian CVD Model. Firstly, it is capable to predict risks for all the main CVD 
events. This is of such importance as avoids resorting to several data sources 
to populate the model. Secondly, hazard functions to estimate further events 
after non-fatal CHD or CBVD were estimated and clearly reported 12. Thirdly, 
the most relevant risk factors for CVD in the Brazilian population 20,36 were 
taken into account. Finally, a competing risk framework was carried out in 
order to avoid over predictions in yearly estimations.         
  Overall, after adaptation, both male and female models were capable 
to reproduce the observed cumulative incidences 20 with less than 1% of 
absolute difference. In addition, predicted life expectancies matched the 
observed life in less than 1 year of difference. It is noticeable in the calibration 
charts that observed incidences are slightly higher compared to predictions. 
That seems to be reasonable considering that the cohort studied 20 is 
representative for Porto Alegre, the capital city of Rio Grande do Sul (RS) 
state. Population in Porto Alegre corresponds to 18% of individuals in RS. 
Data from National Research of Health 18 pointed out that 5.3% of adults living 
in RS in 2013 were diagnosed with heart disease whereas in Brazil 4.2%. 
Similarly, there were 2.2% of individuals who have experienced stroke at least 
once in RS and in Brazil 1.5% in the same year. It has also been observed a 
higher annual incidence of death due to circulatory diseases in RS since 1990 
compared to the annual incidences of Brazil (in 2011 was 0.074% and 
0.054%, respectively) 1.  
 By comparing male and female predictions, it can be seen that results 
are in concordance with Brazilian real life observations, where men are at 
higher risk of experiencing CHD events and for CBVD, risks are nearly the 
same 8,13. In addition, fatal CVD events are more frequent among men 1,38 and 
women present higher life-expectancy 17.     
 Validation is an important step for any decision analytic model in health 
economics. It is conceptualized as the estimation of how well the model 
reproduces reality 13. External validation is the most important type of 
validation since it compares model results and real-world data 13. It can be 
split in dependent, partially dependent and independent external validation 
according to the way real world data was used. Dependent validation consists 
of using real-world data to fit model parameters and validate it. Partially 
dependent validation uses the same source to build or calibrate part of the 
model but that part does not play an important role on defining the outcome to 
be validated. Finally, independent validation takes into account real-world 
data not used in the model. Although the process of calibration we carried out 
in this study can be understood as a dependent external validation 13, we still 
recommend an independent external validation to be performed using a 
broader representative dataset.    
Potential population eligible for this model 
 Covariance among risk factors was not considered. Thus, profiles 
unlikely to be seen within the population might be generated. In fact, lack of 
fitting between observed and predicted data was mainly related to profiles 
with extreme values of age, SBP, TC, HDL and CPD.     
 Overall, after calibration it was observed that men and women aging 
30-70 years old and presenting at least one of the following risk factors: 
diabetes diagnosis, family history of heart disease, smoker, systolic blood 
pressure between 120-190 mmHg, total cholesterol between 200-300 mg/dL 
or HDL cholesterol under 40 mg/dL are more likely to promote predictions 
similar to observed data. An external validation should be able to corroborate 
what patients included in this wide population are eligible to bring about 
reliable costs and consequences outputs.    
Future     
 There are several studies pointing the family income and level of 
deprivation as whole, as an important independent variable for myocardial 
infarction 39 and as a risk factor to CVD events 40, 41. It is important to highlight 
that observed risks for a given patient’s profile will vary according to his level 
of deprivation. Since Brazil does not have a straightforward tool to comprise 
this independent variable in researches (as SIMD score in Scotland and 
England), the predicted risks from this model depict the average observed in 
Brazilian population. The creation of a score to predict deprivation across 
Brazil is of such a value for the society. Ignoring socioeconomic gradients 
lead to increase of inequalities.   
 There is an important lack of broad longitudinal studies of Brazilian 
population assessing chronic diseases, what prevent the development of 
analytic decision models more accurate. ELSA Brasil (Longitudinal Study of 
Adult’s Health) 42 is an ongoing and promising study to start changing this 
reality. Ideally, replacing hazard functions from this model to others derived 
from the Brazilian population would be the best approach to assure that 
hazards are accurate. However, it is also valuable to carry out an external 
validation as soon as newer data become available with the goal of assessing 
the reliability of this adapted model. Moreover, an appropriate external 
validation shall point out for what patients this model is representative.  
 This analytic decision model can be helpful to face the rising of chronic 
diseases, as obesity and diabetes by assessing interventions to prevent 
primary CVD events in those specific populations. After all, this model 
encompasses the most relevant consequences of such diseases. 
 Limitations 
 Nullifying the independent variable SIMD score is to waive the 
information about differences across the country in regard to level of 
deprivation. Trying to validate this tool in Brazil proved to be extremely time-
consuming and technically questionable. By our understanding the most 
appropriate approach was undertaken in this adaptation. Future researches 
with the intention to create a similar tool in Brazil taking into account its 
singularities shall have a massive impact in public health.    
 The Scottish CVD Policy Model is capable to predict later CVD events 
after first non-fatal episode. We did not find enough data in literature to 
calibrate these predictions. Therefore, we are assuming that secondary 
events happen as observed in SHHEC 12.  
 The importance of each risk factor might vary across different 
populations. Currently, we are able to assure that sex, diabetes, FHHD, SBP, 
TC and smoking are the major independent variables for predicting CVD 
events in Brazil 37. Nevertheless, there are not published data to demonstrate, 
quantitatively, the importance of each of them. Rather than calibrating these 
coefficients, we opted to carry out a trustworthier but more limited approach 
by calibrating linear factors. 
 External validation must be carried out before using this model for 
decision-making.         
CONCLUSION 
 
 The adapted model, named Brazilian Analytic Decision Model for CVD, 
has the purpose of serving as a tool for assessing efficiency of interventions 
to prevent primary CVD events. This model is calibrated in terms of life 
expectancy and incidence of the most common CVD events. It is imperative to 
perform a thorough external validation as data become available in order to 
identify eligible population and assure reliability. 
 
